Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.22.2
Commitments and Contingencies (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 40 Months Ended 64 Months Ended
Sep. 30, 2021
USD ($)
payment
Feb. 03, 2020
USD ($)
milestone
Jul. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
therapy
milestone
Aug. 31, 2017
USD ($)
Jun. 30, 2022
USD ($)
payment
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
payment
Jun. 30, 2021
USD ($)
Dec. 31, 2018
unit
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Aug. 31, 2019
USD ($)
Operating Leased Assets [Line Items]                                  
Selling, general and administrative           $ 2,784 $ 7,404 $ 14,468 $ 12,751                
Payment received     $ 2,000                            
Period after public launch to terminate agreement     3 years                            
Percentage of net present value of royalty payments     75.00%                            
Aevi                                  
Operating Leased Assets [Line Items]                                  
Milestone payment               0                  
Aevi                                  
Operating Leased Assets [Line Items]                                  
Number of milestones | milestone   2                              
Contingent consideration   $ 6,500                              
Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of milestones | milestone       3                          
Contingent consideration       $ 15,000                          
Milestone payment               0                  
AVTX-801, AVTX-802, And AVTX-803 | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of preclinical therapies | therapy       3                          
AVTX-913 | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Number of preclinical therapies | therapy       1                          
Milestone One | Aevi                                  
Operating Leased Assets [Line Items]                                  
Contingent consideration   2,000                              
Milestone One | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                     $ 6,000            
Milestone Two | Aevi                                  
Operating Leased Assets [Line Items]                                  
Contingent consideration   $ 4,500                              
Milestone Two | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                       $ 5,000          
Milestone Three | Ichorion                                  
Operating Leased Assets [Line Items]                                  
Milestone payment               0                  
Milestone Three | Ichorion | Forecast                                  
Operating Leased Assets [Line Items]                                  
Milestone payment                       $ 4,000          
Alto | AVTX-301 Out-License                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                             $ 18,600    
Revenue recognized from milestones to date           0   0                  
ES | AVTX-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Revenue recognized from milestones to date           0   0                  
ES | AVTX-611 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                                 $ 20,000
Revenue recognized from milestones to date           0   0                  
ES | Milestone One | AVTX-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                           $ 6,000      
ES | Milestone Two | AVTX-406 License Assignment                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones                           $ 20,000      
Janssen Pharmaceuticals, Inc. (Janssen) | AVTX-501                                  
Operating Leased Assets [Line Items]                                  
Maximum proceeds from milestones         $ 20,000                        
Revenue recognized from milestones to date           0   0                  
Proceeds from sale         $ 25,000                        
Karbinal Agreement | TRIS Pharma                                  
Operating Leased Assets [Line Items]                                  
Minimum quantity required | unit                   70,000              
Make whole payment per unit (in dollars per share) | $ / shares                   $ 30              
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee                               $ 10,000  
Percent of payments received from sublicensing                               30.00%  
Research and development expense               0 10,000                
Cumulative expense recognized to date           0   0                  
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                               $ 112,500  
AVTX-002 KKC License Agreement | Kyowa Kirin Co., Ltd. (KKC) | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                               $ 75,000  
AVTX-006 Astellas License Agreement | Astellas Pharma, Inc. (Astellas)                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee           500   500                  
Maximum aggregate milestone payment           5,500   5,500                  
Research and development expense               0                  
Cumulative expense recognized to date           500   500                  
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute                                  
Operating Leased Assets [Line Items]                                  
Upfront license fee                         $ 400        
Research and development expense             400 0 400                
Cumulative expense recognized to date           $ 0   $ 0                  
Patent costs                         500        
Selling, general and administrative             $ 500   $ 500                
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone One                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                         24,200        
AVTX-008 Sanford Burnham Prebys License Agreement | Sanford Burnham Prebys Medical Discovery Institute | Milestone Two                                  
Operating Leased Assets [Line Items]                                  
Maximum aggregate milestone payment                         $ 50,000        
Deerfield Obligation | AYTU                                  
Operating Leased Assets [Line Items]                                  
Maximum potential future payments $ 3,000                                
Number of quarterly payments | payment 6         2   2                  
Periodic payment $ 500